Finch Therapeutics Group, Inc.
FNCHDelisted Oct 31, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001733257
Finch Therapeutics Group, Inc. was delisted on Oct 31, 2024; its insiders filed their last Form 4 on Jun 10, 2024; no institution reported holding it in 13F filings for Q3 2024; no superinvestor held it.
Q2 2023 vs. Q1 2023
How the institutions holding Finch Therapeutics Group, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 33 | 17 | −16 |
| SharesConverted for a 1-for-30 split | 318.4K | 246.9K | −71.5K (−22.5%) |
| Value | $3.75M | $2.16M | −$1.60M (−42.5%) |
New holders (1)
Institutions that held Finch Therapeutics Group, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Royal Bank of Canada | 27 | $0 | 0.00% |
Sold out (17)
Institutions that held Finch Therapeutics Group, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Boston Private Wealth LLC | 253,054 | $99.5K |
| Geode Capital Management, LLC | 208,320 | $81.9K |
| MSD Partners, L.P. | 153,397 | $60.3K |
| Ballentine Partners, LLC | 143,603 | $56.4K |
| Proficio Capital Partners LLC | 110,559 | $43.5K |
| Renaissance Technologies LLC | 93,000 | $37.0K |
| Laurion Capital Management LP | 58,000 | $22.8K |
| Millennium Management LLC | 48,669 | $19.0K |
| Northern Trust Corp | 25,259 | $9.93K |
| State Street Corp | 24,479 | $9.62K |
| Boothbay Fund Management, LLC | 23,887 | $9.39K |
| Charles Schwab Investment Management Inc | 18,783 | $7.38K |
| Wealthsource Partners, LLC | 18,000 | $7.07K |
| HighTower Advisors, LLC | 13,831 | $5.00K |
| Advisor Group Holdings, Inc. | 249 | $96 |
| Group One Trading, L.P. | 100 | $39 |
| Simplex Trading, LLC | 461 | $0 |